Janney Montgomery Scott
AKRO

Janney Montgomery Scott’s Akero Therapeutics AKRO Stock Holding History

Janney Montgomery Scott’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,810
Closed -$203K – 2855
2025
Q2 		$203K Buy
+3,810
New +$173K ﹤0.01% 2565

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janney Montgomery Scott's AKRO Position: Q3 2025 in Review

Janney Montgomery Scott sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 3,810 shares — an estimated $203K sold.

Janney Montgomery Scott first reported a position in AKRO in Q2 2025 and held it in 1 quarter. The position peaked at $203K in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Janney Montgomery Scott reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Janney Montgomery Scott sold 3,810 Akero Therapeutics shares in Q3 2025, an estimated $203K.
  • Janney Montgomery Scott first reported a position in Akero Therapeutics in Q2 2025 and held it in 1 quarter.
  • Janney Montgomery Scott's Akero Therapeutics position peaked at $203K in Q2 2025.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Janney Montgomery Scott's 13F filing for Q3 2025, filed 27 Oct 2025.